[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416613":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":41,"centralContacts":46,"locations":53,"responsibleParty":70,"collaborators":51,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":51,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":51,"enrollmentInfo":82,"targetDuration":51,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":51,"overallStatus":56,"whyStopped":51,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Tanta University","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"nonselective beta blocker group","EXPERIMENTAL","Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.",[13,14],"Drug: nonselective beta blocker","Drug: alendronate sodium",{"label":16,"type":10,"description":17,"interventionNames":18},"cardio-selective beta blocker group","Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.",[19,14],"Drug: cardio-selective beta blocker group",{"label":21,"type":22,"description":23,"interventionNames":24},"Control group","PLACEBO_COMPARATOR","Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once\u002Fweek, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.",[14],[26,32,36],{"type":27,"name":28,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","nonselective beta blocker",[9],[31],"Inderal",{"type":27,"name":16,"description":16,"armGroupLabels":33,"otherNames":34},[16],[35],"concor",{"type":27,"name":37,"description":37,"armGroupLabels":38,"otherNames":39},"alendronate sodium",[21,16,9],[40],"alendronate",[42],{"name":43,"affiliation":44,"role":45},"Mona Abd El-Rafea Abdo, PH D","Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Sherief Abd-Elsalam, ass. prof.","CONTACT","00201147773440",null,"sheriefabdelsalam@yahoo.com",[54],{"facility":55,"status":56,"city":57,"state":51,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Sherief Abd-Elsalam","RECRUITING","Tanta","35127","Egypt","EG",{"type":62,"coordinates":63},"Point",[64,65],31.00192,30.78847,{"lat":65,"lon":64},[68],{"name":69,"role":49,"phone":50,"phoneExt":51,"email":52},"sherief abd-elsalam, ass. prof",{"type":71,"investigatorFullName":55,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"SPONSOR_INVESTIGATOR","Ass. Prof. Tropical Medicine","100416613","phase-3-clinical-study-evaluating-beta-blockers-use-and-fracture-risk-in-patients-with-primary-osteoporosis-100416613",false,"NCT04704947","Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","Inclusion Criteria:\n\n* • Male \\& female osteoporotic patient aged ≥ 50 years\n\n  * Hypertensive \\& normotensive patients\n  * BMD T-score ≥ 2.5 or more SD below peak bone mass\n\nExclusion Criteria:\n\n* Patients on drugs that may improve osteoporosis disease state such as:\n\n  * Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.\n\nPatients on drugs that may worsen osteoporosis disease state such as:\n\n• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.","ALL","50 Years",{"count":83,"type":84},50,"ESTIMATED","INTERVENTIONAL",[87],"PHASE3","Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis",[90],"Beta Blocker Toxicity","2021-01-09",{"date":93,"type":94},"2021-01-12","ACTUAL",{"date":96,"type":94},"2017-10-01",{"date":98,"type":84},"2030-10-01",{"name":55,"class":6},1]